BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36973268)

  • 1. Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.
    Wu Y; Terekhanova NV; Caravan W; Naser Al Deen N; Lal P; Chen S; Mo CK; Cao S; Li Y; Karpova A; Liu R; Zhao Y; Shinkle A; Strunilin I; Weimholt C; Sato K; Yao L; Serasanambati M; Yang X; Wyczalkowski M; Zhu H; Zhou DC; Jayasinghe RG; Mendez D; Wendl MC; Clark D; Newton C; Ruan Y; Reimers MA; Pachynski RK; Kinsinger C; Jewell S; Chan DW; Zhang H; Chaudhuri AA; Chheda MG; Humphreys BD; Mesri M; Rodriguez H; Hsieh JJ; Ding L; Chen F
    Nat Commun; 2023 Mar; 14(1):1681. PubMed ID: 36973268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
    Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
    BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAP1-Mutated Clear Cell Renal Cell Carcinoma.
    Gallan AJ; Parilla M; Segal J; Ritterhouse L; Antic T
    Am J Clin Pathol; 2021 Apr; 155(5):718-728. PubMed ID: 33210135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma.
    Yu Z; Lv Y; Su C; Lu W; Zhang R; Li J; Guo B; Yan H; Liu D; Yang Z; Mi H; Mo L; Guo Y; Feng W; Xu H; Peng W; Cheng J; Nan A; Mo Z
    Cancer Res; 2023 Mar; 83(5):700-719. PubMed ID: 36607615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
    Liao L; Testa JR; Yang H
    Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma.
    Miura Y; Inoshita N; Ikeda M; Miyama Y; Oki R; Oka S; Kondoh C; Ozaki Y; Tanabe Y; Kurosawa K; Urakami S; Kohno T; Okaneya T; Takano T
    Urol Oncol; 2017 Jun; 35(6):386-391. PubMed ID: 28284891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Renal Cell Carcinoma in Mice:
    Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
    Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
    da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
    Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma.
    da Costa WH; da Cunha IW; Fares AF; Bezerra SM; Shultz L; Clavijo DA; da Silva DV; Netto GJ; Guimaraes GC; Cassio Zequi S
    Urol Oncol; 2018 May; 36(5):243.e1-243.e8. PubMed ID: 29426696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma.
    Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
    Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
    Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
    Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
    Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
    Liu T; Xia Q; Zhang H; Wang Z; Yang W; Gu X; Hou T; Chen Y; Pei X; Zhu G; He D; Li L; Xu S
    Aging (Albany NY); 2020 Nov; 12(21):21809-21836. PubMed ID: 33177244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM6B induces epithelial-mesenchymal transition and enhances clear cell renal cell carcinoma metastasis through the activation of SLUG.
    Li Q; Hou L; Ding G; Li Y; Wang J; Qian B; Sun J; Wang Q
    Int J Clin Exp Pathol; 2015; 8(6):6334-44. PubMed ID: 26261509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.
    Mehdi A; Riazalhosseini Y
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.